Literature DB >> 17699300

Surrogate end points for clinical trials of kidney disease progression.

Lesley A Stevens1, Tom Greene, Andrew S Levey.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 17699300     DOI： 10.2215/CJN.00600206

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  49 in total

1.  Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease.

Authors:  Enrique Morales; Jara Caro; Eduardo Gutierrez; Angel Sevillano; Pilar Auñón; Cristina Fernandez; Manuel Praga
Journal:  Kidney Int       Date:  2015-08-26       Impact factor: 10.612

Review 2.  MRI-detectable nanoparticles: the potential role in the diagnosis of and therapy for chronic kidney disease.

Authors:  Jennifer R Charlton; Scott C Beeman; Kevin M Bennett
Journal:  Adv Chronic Kidney Dis       Date:  2013-11       Impact factor: 3.620

Review 3.  Integrating albuminuria and GFR in the assessment of diabetic nephropathy.

Authors:  George Jerums; Sianna Panagiotopoulos; Erosha Premaratne; Richard J MacIsaac
Journal:  Nat Rev Nephrol       Date:  2009-07       Impact factor: 28.314

4.  Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study.

Authors:  Phyllis August; Regina M Hardison; Fadi G Hage; Oscar C Marroquin; Janet B McGill; Yves Rosenberg; Michael Steffes; Barry M Wall; Mark Molitch
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 8.237

Review 5.  Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis.

Authors:  Min Jun; Tanvir Chowdhury Turin; Mark Woodward; Vlado Perkovic; Hiddo J Lambers Heerspink; Braden J Manns; Marcello Tonelli; Brenda R Hemmelgarn
Journal:  J Am Soc Nephrol       Date:  2015-01-02       Impact factor: 10.121

6.  Temporary perioperative decline of renal function is an independent predictor for chronic kidney disease.

Authors:  Jan-Peter van Kuijk; Willem-Jan Flu; Michel Chonchol; Sanne E Hoeks; Tamara A Winkel; Hence J M Verhagen; Jeroen J Bax; Don Poldermans
Journal:  Clin J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 8.237

7.  Doubling of serum creatinine: is it appropriate as the endpoint for CKD? Proposal of a new surrogate endpoint based on the reciprocal of serum creatinine.

Authors:  Noriko Takeuchi; Emi Takenoshita; Fumino Kato; Tomoko Terajima; Makoto Ogawa; Satoshi Suzuki; Takayuki Fujii; Eriko Kobayashi; Tomoya Sakurada; Nobunori Satoh; Shiro Ueda
Journal:  Clin Exp Nephrol       Date:  2010-11-09       Impact factor: 2.801

8.  Joint Modeling of Repeated Measures and Competing Failure Events In a Study of Chronic Kidney Disease.

Authors:  Wei Yang; Dawei Xie; Qiang Pan; Harold I Feldman; Wensheng Guo
Journal:  Stat Biosci       Date:  2016-12-27

9.  Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy?

Authors:  Alessandro Doria; Monika A Niewczas; Paolo Fiorina
Journal:  Semin Nephrol       Date:  2012-09       Impact factor: 5.299

10.  Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group.

Authors:  Alexandra Peyser; Nathaniel Machardy; Freya Tarapore; Jacqueline Machardy; Leslie Powell; Debbie S Gipson; Virginia Savin; Cynthia Pan; Theresa Kump; Suzanne Vento; Howard Trachtman
Journal:  BMC Nephrol       Date:  2010-01-29       Impact factor: 2.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.